Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approval Round Up: Keytruda, Opdivo Add Claims

Executive Summary

Cancer supplements took center stage for US FDA this week, but OptiNose Inc.'s corticosteroid Xhance also took a bow.

Advertisement

Related Content

CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End
Bristol's Opdivo Diversifies Options In Liver Cancer
FDA Eyeing Other PD-1/L1 Drugs With Clinical Hold On Keytruda Myeloma Trials
Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown
Merck & Co. Strengthening Its Strong Position In Immuno-Oncology
Keeping Track: Oncology Filings Galore In Run-Up To ASCO Meeting
Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals
BioCryst Flu Treatment’s Success May Hinge On Government Contract

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS121625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel